Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 7/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | POLA1 | P09884 | 1/20 | 0.50 |
| ▸ | POLD1 | P28340 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | ALB | P02768 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23440065 | 0.91 | TK1 (0.67) | TK1POLBPOLA1POLD1 | |
| SCHEMBL8883 | 0.91 | TK1 (0.67) | TK1POLBPOLA1POLD1 | |
| SCHEMBL26757571 | 0.91 | TK1 (0.67) | TK1POLBPOLA1POLD1 | |
| SCHEMBL28774920 | 0.91 | TK1 (0.67) | TK1POLBPOLA1POLD1 | |
| SCHEMBL9549776 | 0.90 | TK1 (0.53) | TK1POLBPOLA1POLD1BCHE | |
| SCHEMBL13245040 | 0.90 | TK1 (0.57) | TK1POLBPOLA1POLD1BCHE | |
| SCHEMBL6420653 | 0.89 | TK1 (0.58) | TK1POLBPOLA1POLD1BCHE | |
| SCHEMBL23440064 | 0.89 | TK1 (0.54) | TK1POLBPOLA1POLD1BCHE | |
| SCHEMBL24239527 | 0.88 | TK1 (0.57) | TK1POLBPOLA1POLD1ALB | |
| SCHEMBL17151599 | 0.88 | TK1 (0.57) | TK1POLBPOLA1POLD1ALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240026353-A1 | COMPOUNDS AND METHODS FOR MODULATING SCN2A | IONIS PHARMACEUTICALS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230054720-A1 | Antisense Oligonucleotides Targeting ATXN3 | HOFFMANN-LA ROCHE INC. | 2023-02-23 | — | — | US | disclosed |
| US-20220204973-A1 | Antisense Oligonucleotide for Targeting Progranulin | HOFFMANN LA ROCHE (US) | 2022-06-30 | — | — | US | disclosed |
| US-20210388357-A1 | OLIGONUCLEOTIDE AGONISTS TARGETING PROGRANULIN | HOFFMANN-LA ROCHE INC. (US) | 2021-12-16 | — | — | US | disclosed |
| US-20210123054-A1 | OLIGONUCLEOTIDES FOR MODULATING TAU EXPRESSION | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2021-04-29 | — | — | US | disclosed |
| US-10865414-B2 | Modulators of DNM2 expression | IONIS PHARMACEUTICALS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| US-20190241896-A1 | MODULATORS OF DNM2 EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2019-08-08 | — | — | US | disclosed |
| US-20170349897-A1 | COMPOSITIONS FOR MODULATING C9ORF72 EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2017-12-07 | — | — | US | disclosed |
| WO-2017053722-A1 | MODULATORS OF KRAS EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2017-03-30 | — | — | WO | disclosed |
| WO-2016168592-A2 | COMPOSITIONS FOR MODULATING C9ORF72 EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2016-10-20 | — | — | WO | disclosed |
| WO-2015168635-A2 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-11-05 | — | — | WO | disclosed |
| WO-2015168618-A2 | COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-11-05 | — | — | WO | disclosed |
| WO-2015168532-A2 | COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-11-05 | — | — | WO | disclosed |
| WO-2015153800-A2 | COMPOSITIONS FOR MODULATING SOD-1 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-10-08 | — | — | WO | disclosed |
| WO-2015100394-A1 | MODULATION OF ANGIOPOIETIN-LIKE 3 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-07-02 | — | — | WO | disclosed |
| WO-2015010135-A2 | COMPOSITIONS FOR MODULATING TAU EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-01-22 | — | — | WO | disclosed |
| WO-2014179626-A2 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014179627-A2 | COMPOSITIONS AND METHODS FOR MODULATING HBV AND TTR EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240026353-A1 | COMPOUNDS AND METHODS FOR MODULATING SCN2A | SCN2A, SCN1A, SCN1B | TK1 4840/4885POLB 3256/4885POLA1 3623/4885 |
| US-20230054720-A1 | Antisense Oligonucleotides Targeting ATXN3 | ATXN2, ATXN2L, ATXN10 | TK1 891/4885POLB 173/4885POLA1 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.